Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Guardant Health (NASDAQ:GH) had its target price upped by research analysts at JPMorgan Chase & Co. from $130.00 to $135.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 41.07% from the stock’s previous close.

A number of other equities research analysts have also weighed in on GH. Leerink Partners raised their price objective on shares of Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, February 20th. Canaccord Genuity Group increased their target price on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. Citigroup raised their price target on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Wells Fargo & Company lifted their price target on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Finally, Stifel Nicolaus increased their price objective on Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 20th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus target price of $129.16.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $95.70 on Friday. Guardant Health has a one year low of $36.36 and a one year high of $120.74. The company has a market cap of $12.69 billion, a PE ratio of -28.23 and a beta of 1.48. The business has a 50-day simple moving average of $88.93 and a 200-day simple moving average of $96.92.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter last year, the business posted ($0.62) earnings per share. The firm’s quarterly revenue was up 39.4% compared to the same quarter last year. On average, sell-side analysts predict that Guardant Health will post -2.87 earnings per share for the current fiscal year.

Insider Activity at Guardant Health

In other news, Director Musa Tariq sold 348 shares of Guardant Health stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32. Following the sale, the director owned 8,394 shares in the company, valued at approximately $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Terilyn J. Monroe sold 3,832 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the completion of the sale, the insider directly owned 20,990 shares of the company’s stock, valued at approximately $1,945,353.20. This trade represents a 15.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,596 shares of company stock valued at $775,767 in the last ninety days. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Emerald Advisers LLC boosted its stake in Guardant Health by 24.8% during the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock worth $54,558,000 after purchasing an additional 173,281 shares during the period. Knights of Columbus Asset Advisors LLC purchased a new stake in shares of Guardant Health in the third quarter valued at about $1,554,000. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Guardant Health by 54.4% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock worth $18,835,000 after buying an additional 106,263 shares during the last quarter. Erste Asset Management GmbH increased its position in Guardant Health by 10.4% in the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after acquiring an additional 66,617 shares during the period. Finally, Segall Bryant & Hamill LLC raised its stake in Guardant Health by 57.8% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after acquiring an additional 111,822 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Key Headlines Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant Health reported Q1 2026 revenue of $301.7 million, well above Wall Street expectations, with revenue up 48% year over year and oncology test volume rising sharply. Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The company beat earnings estimates with a smaller-than-expected quarterly loss of $0.45 per share, signaling improving operating performance. Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
• Positive Sentiment: Guardant Health raised its 2026 revenue guidance, reinforcing confidence in continued demand and execution. Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: JPMorgan Chase & Co. raised its price target on GH to $135 from $130 and reiterated an overweight rating, implying further upside from current levels. Benzinga report on JPMorgan price target increase
• Neutral Sentiment: Investors are also digesting the company’s earnings call transcript and presentation for more detail on management’s outlook and product momentum. Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.